Digest Network Come funziona
Network
/
Società
Be
Non verificato

Beren Therapeutics P.B.C.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

8 comunicati stampa

Guarda tutti i comunicati
15/10/2026
Infanzia
Assistenza all'Infanzia
Biotecnologia
Medicina - Varie
Salute
Vetrine/Shopping
Farmaceutica
Eventi
Industria
Beren Therapeutics Presents New Adrabetadex Data Showing Preservation of Neurological Function for More Than 10 Years in Children with Infantile-Onset NPC
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
09/09/2026
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Beren Therapeutics Launches ‘Test for NPC’ to Help Identify People with Niemann-Pick Disease, Type C Who Remain Undiagnosed
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
06/08/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Beren Therapeutics Expands Cyclodextrin Intellectual Property Estate with Eight New U.S. Issued Patents
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
10/06/2026
Mercato del lavoro
Industria
Sanità
Associazioni/Professionisti
Famiglia
Farmaceutica
Vetrine/Shopping
Infanzia
Assistenza all'Infanzia
Igiene alimentare
Finanza
Salute
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
29/05/2026
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Eventi
Industria
Beren Therapeutics Announces Six Presentations at the 2026 Ara Parseghian Medical Research Fund (APMRF) Conference
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
28/05/2026
Industria
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Beren Therapeutics Announces FDA Extension of Review Period for New Drug Application (NDA) for Adrabetadex for the Treatment of Infantile-Onset Niemann-Pick Disease, Type C
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
12/03/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Beren Therapeutics Presents Data Supporting the Efficacy of Adrabetadex in Infantile-Onset NPC at 2026 ACMG Clinical Genetics Meeting
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0
23/02/2026
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C
Fonte
Beren Therapeutics P.B.C.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0